Development Discontinued for ANA975 for Hepatitis C Virus Infection

July 27, 2007

Anadys Pharmaceuticals announced that it and Novartis have decided to discontinue the development of ANA975, a Phase Ib compound for the treatment of hepatitis C virus (HCV) infection.

Anadys and Novartis determined that the results received to date from the ongoing 13-week toxicology study, together with the results observed in the previous 13-week toxicology study, do not support further clinical evaluation of chronic daily dosing of ANA975 in HCV patients.

Anadys said it will continue development of ANA773, another TLR7 agonist prodrug distinct from ANA975, and expects to file an IND by the end of the year.